Biocartis

Biocartis is a molecular diagnostics company based in Mechelen, Belgium, founded in 2007 and publicly listed on the Euronext Brussels exchange. The company aims to make personalized medicine accessible worldwide by providing convenient and rapid molecular testing suitable for any laboratory. At the heart of Biocartis' offerings is the Idylla™ Platform, a fully automated real-time PCR system. This platform delivers quick and accurate molecular diagnostic results directly in-house, enabling faster treatment decisions without the need for specialized expertise or complex infrastructure. Biocartis primarily focuses on oncology, offering a range of molecular diagnostic tests for various cancers, including melanoma, colorectal, lung, brain, blood, and breast cancers. The Idylla platform is designed to be user-friendly for laboratory staff and medical professionals, facilitating near-patient testing and efficient molecular analysis for diagnosis and treatment monitoring.

• Employees 530
• Founded 2007
• Annual Revenue $61656000
• Total Funding $95665317